|
|
| |
 |
InsuLine Medical was founded in Israel by an experienced team of engineers, specializing in the medical device arena, and the diabetes care market.
InsuLine’s mission is to develop and market technologies designed to the clinical effectiveness of devices and drugs, for type I and type II diabetics.
The company's first line of products aims to target the current delay between post meal glucose increase and the relatively slow absorption of subcutaneously injected insulin. This delay may contributes to high post meal glucose increase.
Insuline’s technology enables faster insulin absorption by increasing local blood perfusion at the injection site which enables faster clearance of the insulin from the injection site to the blood system. Insuline is developing two lines of products; the InsuPatch™ device, for use with infusion pumps and the InsuPad™ device, to be used with insulin injections.
As of today, the company has conducted a series of over 100 human clinical studies demonstrating the safety and effectiveness of the first generation InsuPatch device. The product has received a CE mark enabling it to be marketed in the EU and the company is now seeking FDA approval for it.
The company has also filed for several patents to protect its technology and related devices and methods. |
|
|
|
